Vertex Pharmaceuticals (VRTX) EVP Bozic Sells $471K of Stock
Vertex's EVP and CMO Carmen Bozic sold 1,020 shares on June 18, 2026, as part of a planned transaction.
Reviewed by automated data checks against the source filing. How we make and check alerts
Carmen Bozic, EVP and CMO at Vertex Pharmaceuticals Incorporated ($VRTX), sold 1,020 shares at an average price of $462.17, worth about $471,413.40, on June 18, 2026. The trade was reported to the SEC in a Form 4 filing and was made under a pre-arranged Rule 10b5-1 trading plan.
Since the trade, $VRTX is up 6.3% after 1 week, up 6.4% after 1 month and up 10.7% to date (from the $451.63 close on Jun 18, 2026).
VRTX
Vertex Pharmaceuticals Incorporated
Key Points
- Carmen Bozic, EVP and CMO of Vertex Pharmaceuticals, sold 1,020 shares at an average price of $462.17 on June 18, 2026.
- Vertex Pharmaceuticals has a market cap of approximately $118.5 billion and a P/E ratio of 27.7, with shares trading near $466.79 on Wednesday.
- Analysts maintain a positive outlook on Vertex, with a consensus rating of 'buy' and a mean price target of $548.69.
Get $VRTX trade alerts by text
We text you when insiders, Congress or big funds trade $VRTX. Free.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Vertex Pharmaceuticals Incorporated alert may contain errors. Disclosures
On June 18, 2026, Carmen Bozic, Executive Vice President and Chief Medical Officer of Vertex Pharmaceuticals Incorporated, sold 1,020 shares of the company. The shares were sold at an average price of $462.17, amounting to a total transaction value of $471,413. This sale was conducted as part of a pre-arranged trading plan.
Insider Buying and Selling at Vertex Pharmaceuticals Incorporated
Carmen Bozic has been active in selling Vertex Pharmaceuticals shares recently. On June 15, she sold 4,062 shares at $450 each, and on June 5, she sold another 1,745 shares at the same price. Additionally, other executives like Joy Liu, EVP and Chief Legal Officer, sold 828 shares at $439.91 on June 1, 2026.
Vertex Pharmaceuticals Incorporated Stock Down 8.2%
Shares of NasdaqGS:VRTX traded near $466.79 on Wednesday. Vertex Pharmaceuticals, a biotechnology firm based in Boston, has a market cap of approximately $118.5 billion. The company has a P/E ratio of 27.7 and a forward P/E of 21.7. Its stock has ranged from a low of $362.50 to a high of $507.92 over the past 52 weeks. The company maintains a strong financial position with a current ratio of 3.02 and a quick ratio of 2.38.
Analysts Set New Price Targets
On May 6, 2026, Barclays maintained its 'buy' rating for Vertex Pharmaceuticals with a price target of $615. Similarly, Morgan Stanley and Bernstein both maintained 'buy' ratings on May 5, with targets of $616 and $572, respectively. The consensus among analysts is a 'buy' recommendation, with a mean price target of $548.69 based on 29 analyst opinions.
About Vertex Pharmaceuticals
Vertex Pharmaceuticals Incorporated is a biotechnology company headquartered in Boston, Massachusetts. It focuses on developing transformative medicines for serious diseases, particularly in specialty markets like cystic fibrosis, sickle cell disease, and beta thalassemia. Vertex's flagship products include TRIKAFTA/KAFTRIO and SYMDEKO/SYMKEVI for cystic fibrosis, among others. The company is led by CEO Dr. Reshma Kewalramani and employs approximately 6,400 people.
Bottom Line
Carmen Bozic's planned sale of Vertex Pharmaceuticals shares is part of a series of insider transactions, reflecting routine portfolio management. Vertex remains a significant player in the biotechnology sector, with strong financials and a positive analyst outlook. Investors often keep an eye on such insider activities as part of their broader investment strategy.
Related Filing Alerts
Source: Carmen Bozic's Form 4 filing on $VRTX (Jun 18, 2026). Find the original filing: VRTX Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts